Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NT5E | P21589 | 2/20 | 0.49 |
| ▸ | TYMP | P19971 | 1/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.41 |
| ▸ | AHCY | P23526 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3163908 | 1.00 | LMNA (0.53) | LMNANT5ETYMPSTING1ABCB1 | |
| SCHEMBL13970745 | 1.00 | LMNA (0.53) | LMNANT5ETYMPSTING1ABCB1 | |
| SCHEMBL14615870 | 0.89 | TYMP (0.50) | LMNATYMPSTING1ABCB1GSK3A | |
| SCHEMBL20059072 | 0.89 | TYMP (0.50) | LMNATYMPSTING1ABCB1GSK3A | |
| SCHEMBL20180318 | 0.88 | NT5E (0.58) | LMNANT5E | |
| SCHEMBL10444341 | 0.87 | NT5E (0.55) | LMNANT5ESTING1BCHE | |
| SCHEMBL9850217 | 0.87 | LMNA (0.51) | LMNANT5ESTING1ABCB1BCHE | |
| SCHEMBL9850211 | 0.87 | LMNA (0.51) | LMNANT5ESTING1ABCB1BCHE | |
| SCHEMBL5389026 | 0.86 | LMNA (0.46) | LMNATYMPSTING1ABCB1GSK3A | |
| SCHEMBL14593730 | 0.86 | LMNA (0.46) | LMNATYMPSTING1ABCB1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0852499-B1 | THERAPEUTIC AZIDE COMPOUNDS | UNIV GEORGIA RES FOUND (US) | 2010-03-03 | — | — | EP | disclosed |
| US-6949521-B2 | Therapeutic azide compounds | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20010036930-A1 | Therapeutic azide compounds | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2001-11-01 | — | — | US | disclosed |
| EP-0852499-A1 | THERAPEUTIC AZIDE COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1998-07-15 | — | — | EP | disclosed |
| EP-0428109-A2 | Deoxyfluoronucleoside process | Bristol-Myers Squibb Company (US) | 1991-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036930-A1 | Therapeutic azide compounds | ADA, ADK, DCK | LMNA 1731/4885NT5E 332/4885TYMP 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.